Search company, investor...

Compare arstasis vs Micrus Endovascular

Customers evaluate the quality of arstasis's products using the following success metrics.

Overview

arstasis is 20 yrs old and is based in United States.

Arstasis develops vascular access devices designed to provide better solutions for arterial closure in catheterization procedures. The AXERA Access Device is a femoral artery access tool that quickly creates a longer and shallower angle arteriotomy, resulting in significant tissue-upon-tissue overlap through the artery. Upon sheath removal, arterial pressure decreases across this longer Arstaotomy channel providing an excellent environment for clot formation and rapid hemostasis. The AXERA Device's Arstaotomy Procedure requires only minimal compression to provide secure closure with no foreign body implants - eliminating the risk of infections and thomboembolic events related to implants. The Arstaotomy Procedure promotes rapid hemostasis resulting in excellent patient comfort with decreased bed rest and quicker ambulation.

Micrus Endovascular

Micrus Endovascular is 28 yrs old and is based in United States.

Micrus Endovascular develops, manufactures and markets both implantable and disposable medical devices used in the treatment of cerebral vascular diseases. Micrus is developing products for the treatment of hemorrhagic and ischemic stroke. Both hemorrhagic and ischemic stroke are significant causes of death worldwide. Micrus product lines consist of endovascular systems that enable a physician to gain access to the brain in a minimally invasive manner through the vessels of the arterial system. Micrus also sells accessory devices and products used in neurovascular procedures.

Founded Year